Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedA note explains that PubMed publications shown are auto-filled and may not pertain to the study. Revision: v3.3.2 is now listed.SummaryDifference0.1%

- Check27 days agoChange DetectedThe funding-status notice about potential data updates due to government funding lapses is removed, along with the associated operating-status guidance. The page no longer displays the disclaimer and the link to opm.gov for updates.SummaryDifference0.3%

- Check42 days agoChange DetectedThe study record shows updated last update dates (e.g., Last Update Posted 2025-05-07) with no changes to the trial design or eligibility.SummaryDifference0.4%

- Check71 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference3%

- Check78 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0, indicating a newer release.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2; the 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.